# Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

> **NCT07174570** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 39 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8

## Interventions

- **DRUG:** Celecoxib
- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Tremelimumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biopsy Procedure

## Key facts

- **NCT ID:** NCT07174570
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-02
- **Primary completion:** 2026-11-13
- **Final completion:** 2027-11-13
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174570, "Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07174570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*